Grace Davison Discovery Sciences was formed through the acquisitions of Alltech, Davisil, Flexit, Grom, Jones Chromatography, MODcol, and Vydac.
Waters introduced the SystemsQT qualification tool for Waters HPLC and Waters ACQUITY UltraPerformance LC (UPLC) systems in an Empower software environment.
Labcyte introduces the Echo 520 liquid handler, which was developed for the medium-throughput laboratory.
ESA Biosciences has launched new HPLC systems designed to help expedite drug-metabolism studies and support medicinal chemistry efforts by electrochemically synthesizing significant quantities of difficult-to-obtain metabolites.
Millipore provides syringe filters, membranes, and holders in many configurations that are designed and manufactured to maximize ultra-high pressure liquid chromatography (UHPLC) system performance.
BTX has introduced a new MicroPoration technology for transfection of 10µl to 100µl sample volumes.
Shimadzu has released the interface software to Waters Empower Chromatography data processing software for controlling Shimadzu’s Prominence HPLC series.
Invetech will showcase its integrated contract development and manufacturing services at LabAutomation2008.
Researchers in Germany’s A&M Labs have validated a method that uses Thermo Scientific high-Field Asymmetric waveform Ion Mobility Spectrometry (FAIMS) technology to remove interferences from a drug analysis.
Eksigent announces the addition of a NanoLC MALDI Spotting System to its nanoflow chromatography product line.
The Association for Laboratory Automation (ALA) and the Laboratory Robotics Interest Group (LRIG), announced that 15 companies were selected for Late Night with LRIG – A Rapid Fire Innovation Session.
The Association for Laboratory Automation (ALA) announced the finalists for its $10,000 Innovation Award, which recognizes outstanding innovation and contributions to automation technologies in the laboratory.
Menveo, a vaccine in development by Novartis, may protect infants using a schedule beginning at two months of age against four of the most common causes of meningococcal disease.
Takeda Global Research & Development Center submitted a New Drug Application to the FDA for alogliptin, a highly selective dipeptidyl peptidase-4 inhibitor under investigation for the treatment of type 2 diabetes.
The U.S. National Cancer Institute has filed a protocol for a Phase 1/2 clinical trial for patients with metastatic ovarian, peritoneal, or fallopian tube cancers using concurrent systemic and intraperitoneal administration of Reolysin, Oncolytics Biotech's’ formulation of the human reovirus.